JPH08509245A - Use of ceruletide diethylamine salt in the treatment of psoriasis - Google Patents

Use of ceruletide diethylamine salt in the treatment of psoriasis

Info

Publication number
JPH08509245A
JPH08509245A JP7521701A JP52170195A JPH08509245A JP H08509245 A JPH08509245 A JP H08509245A JP 7521701 A JP7521701 A JP 7521701A JP 52170195 A JP52170195 A JP 52170195A JP H08509245 A JPH08509245 A JP H08509245A
Authority
JP
Japan
Prior art keywords
patient
psoriasis
lesions
badge
diethylamine salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7521701A
Other languages
Japanese (ja)
Inventor
フエオクハロブナ・ケレシエバ,ラマラ
Original Assignee
テオカール・リミテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テオカール・リミテツド filed Critical テオカール・リミテツド
Publication of JPH08509245A publication Critical patent/JPH08509245A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2207Gastrins; Cholecystokinins [CCK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Abstract

(57)【要約】 乾癬の治療におけるセルレチドジエチルアミン塩の使用を提供する。   (57) [Summary] Provided is the use of ceruletide diethylamine salt in the treatment of psoriasis.

Description

【発明の詳細な説明】乾癬の治療におけるセルレチドジエチルアミン塩の使用 本発明は、乾癬を治療するためのセルレチドジエチルアミン塩(Takus)の使 用に関する。 この皮膚疾患の治療は今まではエトレチナート(Tigason)を用いて行われて きたが、エトレチナートは、乾癬による皮膚の角化の原因となり得る損傷にわず かに影響を与えるのみである。さらに該物質は、特に長期にわたる治療の間に耐 性及び催奇作用を生起させ得る。 先ずHy1a caerulea(オーストラリア産のカエル)の皮膚から抽出され、次い で合成により製造された周知のデカペプチドであるセルレチドは、次式: を有し、そのジエチルアミン塩は「Takus」という商標名で市販されている。 治療上では、セルレチドジエチルアミン塩は、胃液分泌の刺激剤として使用さ れる他に、胆嚢及び脾臓の機能状態を調べるときの診断薬として用いられている 。 驚くべきことには、セルレチドジエチルアミン塩を乾癬 の治療に用いて極めて良好な結果が得られることが見いだされた。 セルレチドジエチルアミン塩が、滴状乾癬、模様状乾癬、円形乾癬、地図状乾 癬及び脂漏性乾癬といった種々の形態の乾癬の治療に有効であることが12人の ボランティア(男性9人、女性3人)において確認されている。該物質は、他種 の薬剤との相乗的薬理学的作用を回避するために単独で用いられてきたが、それ によって皮膚疾患に対する該物質自体の正の作用を評価することが可能であった 。 セルレチドジエチルアミン塩を2.5〜5.0μgの範囲の用量で一回筋肉内 注射により投与すると、例外なく、全ての患者において疾患が著しく改善され、 そのような改善は1〜3カ月の間続く。 投与後第1日目に、睡眠の改善、精神状態の安定及び痒みの減少が認められた 。 1〜2週間の間に、鱗屑は消滅し、バッジ状病変部(badges)は著しく減少し て、軟らかく白っぽくなって、最後には消滅したことが認められた。 通常、滴状乾癬の治療にはセルレチドジエチルアミン塩を一回注射するだけで 十分である。 特に直りにくいバッジ状病変部が存在する場合には、製剤をセルレチドジエチ ルアミン塩に対する患者の個々の感受性に注意を払いつつ、2.5〜5.0μg の用量で更に注射する。 病変部の皮膚はセルレチドジエチルアミン塩を用いて治療している間に正常な 色を取り戻したが、セルレチドジエチルアミン塩の代わりに慣用タイプの軟膏( 例えば、水銀軟膏)を用いると、常に色素脱失が認められた。 アルコール中毒症を伴う乾癬の場合には、セルレチドジエチルアミン塩を一回 投与しただけで皮膚障害が完全に正常化し、この正の作用は約5〜6カ月も続い た。又アルコール中毒症が再発した後では、アルコールを再び飲み始めてから最 初の1〜2カ月の間に乾癬の再発が認められた。実施例 実施例1:患者 A.V.(男性、20歳、独身、コック) 診断:円形乾癬、アルコール中毒症。 既往歴:最初の乾癬の兆候は、患者が15歳のときに経験した自動車事故の後で 見られた。 自動車事故の2〜3カ月後、患者の肘にしみが、また、患者の腕、脚、胸及び 肩にバッジ状病変部が広がっている のが認められた。 特に冬季に病状が再燃した。父親から複雑な遺伝を受けついでいた患者は、1 7歳のときに慢性アルコール中毒症になり、その間に病状も悪化したことが認め られた。 タール軟膏、コルチゾンリニメント剤、ビタミン剤及び鎮静剤による治療を繰 り返し行ったが、何ら改善が得られなかった。バッジ状病変部は消えてしまうこ とさえあったが、肘や膝のような別の場所に再び現れたりした。 患者は、診察の際に、肘、腕、脚、肩、額及び耳の周りの痒みとバッジ状病変 部の存在を訴えた。 患者の額にあったバッジ状病変部の大きさは2.5×3及び5.0×4.0c m2で、左肘の内表面のバッジ状病変部の大きさは6.0×5.0cm2、3.0 ×2.5cm2及び3.0×2.0cm2であり、患者の右肘には、8.0×2. 5cm2、3×2.5cm2の大きさの滴状乾癬(23個のバッジ状病変部)形態 のバッジ状病変部の他、より小さい28個のバッジ状病変部があった。 患者の背中全体に滴状乾癬バッジ状病変部及び硬貨と同じ位の大さの他のバッ ジ状病変部があった。滴状乾癬及び円形乾癬の25個のバッジ状病変部が患者の 左もも側部に あった。殆どが鱗屑で覆われ、最大4.5×5.5cm2の大きさの32個の紫 色のバッジ状病変部が左ももの内側にあった。大きさが0.5×0.5cm2〜 1.8×2.0cm2の範囲の28個のバッジ状病変部が患者の右ももにあった 。 直径0.5×6.0cm2のバッジ状病変部が患者の左脛骨の上前部に認めら れたが、患者の右脛骨の同じ領域は28個の紫色のバッジ状病変部で覆われてい た。セルレチドジエチルアミン塩による治療 4.9μgのセルレチドジエチルアミン塩を一回注射して患者を治療した。 治療したその日のうちに、患者A.V.に、睡眠の改善及び痒みの減少が認め られた。2週間後、バッジ状病変部は軟らかく且つ白っぽくなった。背中のバッ ジ状病変部はリング状に変わった。 1カ月後、患者の額、肘及び脚にあったバッジ状病変部間にスペースが見られ た。 背中のバッジ状病変部は白っぽく半円状になった。脚にあったバッジ状病変部 は減少した。皮膚障害の改善は3カ月にわたる観察の間続き、その間にバッジ状 病変部は全て 消えた。10カ月後でさえ、正の作用が認められた。 その後患者は時折再びアルコールを飲み始め、乾癬が再発してからはアルコー ルを飲むのを止めて、専門のクリニックで41日間のビタミン剤、石英ランプ及 びリニメント剤による定期的な治療を受けた。 クリニックでの治療を終了して3日後に、患者は再びアルコールを飲み始め、 その翌週には、疾患の全症状が再現した。実施された2種の治療を比較してみる と、セルレチドジエチルアミン塩を用いた治療の方がその有利な効果がより長い 期間持続した。 実施例2:患者 N.I.(女性、35歳、慢性胃炎) 診断:模様状乾癬及び滴状乾癬、慢性胃炎。 既往歴:事故の2カ月後に最初の乾癬症状が現れた。患者は不眠症、無月経及び 被刺激性の状態にあった。 事故後数カ月して、打撲傷を受けた部分にいくつかのしみが現れ、患者の胸及 び背中にも数箇所のしみがあった。患者はビタミン剤、鎮静剤及びタール軟膏に よる治療を受けた。 背中と胸のしみは消えたが、新たに顔、腕及び脚にしみが現れた。 しみの治療を受けた箇所の皮膚に色素脱失が見られた。 患者は、入浴後の痒みと、膝、脚、腹部及び腕のバッジ状病変部を訴える。 バッジ状病変部の大きさは、患者の左脚の一つのバッジ状病変部が5.5×6 .0cm2で、患者の右膝の2個のバッジ状病変部は6.5×4.5cm2及び2 .0×3.5cm2であり、滴状形態のバッジ状病変部が患者の胸、背中及び腕 の内側に認められた。セルレチドジエチルアミン塩による治療 4.5μgのセルレチドジエチルアミン塩を一回注射して患者を治療した。 セルレチドの注射による治療後その日のうちに、患者に、被剌激性、痒み及び バッジ状病変部の剥離がなくなったことが認められた。 1週間後に、患者の背中と胸のバッジ状病変部は白っぽくなり、バッジ状病変 部間に小さなスペースが見られた。 色素脱失したバッジ状病変部は再び正常な皮膚の色に戻り、改善状態は全ての バッジ状病変部が消滅するまで約4カ月の間続き、悪化することはなかった。該 期間及び10カ月の観察期間中、該患者には皮膚障害が全く認められな かった。 実施例3:患者 C.A.(男性、33歳、独身、エンジニア) 診断:脂漏性乾癬、慢性腎盂腎炎。 既往歴:7年前、兵役中に乾癬の診断を受けた。バッジ状病変部が額の頭髪近く に現れ、次いで頭皮全体が鱗屑で覆われた。通常、2カ月毎に乾癬の再燃があっ た。水銀軟膏で治療しても一時的に改善されただけで、バッジ状病変部は依然と して消えず、慢性になった。 来院の際、患者は、強烈な痒みや剥離、頭皮のバッジ状病変部及び額の「冠状 」病変部の存在を訴えた。 額の紫色の冠状病変部の大きさは、16×3.8cm2であった。 頭皮の全表面は地図状乾癬で覆われていた。 最も大きく且つ最も厚いバッジ状病変部は耳の後ろにあった。患者はひどい抑 鬱状態にもあった。セルレチドジエチルアミン塩による治療 3.0μgのセルレチドジエチルアミン塩を一回注射して患者を治療した。 患者に、睡眠及び痒みの改善及び精神状態の安定が認め られた。 1週間でバッジ状病変部は薄くなり茶色になった。3週間後、耳の後ろのバッ ジ状病変部は薄く白っぽくなった。 額の冠状病変部に大きなスペースが見られ、冠状病変部は単一部分に分かれ始 めた。皮膚の改善は3カ月間続いた。 最初の注射から4カ月後に2.7μgの第2回目の注射を行った。剥離が著し く減少し、冠状病変部は白っぽくなった。 耳の後ろのバッジ状病変部は減少し、白っぽく薄くなった。 治療を継続し、約12カ月後にも患者の症状に何ら悪化が認められず、これは 、最終治療から得られた結果であった。 実施例4:患者 S.Sh.(22歳、独身、大学生、バスケットボール及び陸 上競技の選手) 診断:胃炎を伴う滴状乾癬。 既往歴:先ず心的葛藤状態により引き起されたひどいストレスの治療を開始して から14カ月後に乾癬のバッジ状病変部が現れた。 秋に症状の再燃が起こった。さらに、高カロリー値を有 するペーストリー、ケーキ及び他の同種製品を食べたときに新しいバッジ状病変 部が現れた。 患者は、ホルモン軟膏、サリチル酸軟膏及び硫黄軟膏、ビタミン剤、石英及び 日光浴により自力で治した。 バッジ状病変部は白っぽくなり、色素脱失したしみを残して消えたが、数週間 後に又現れた。 セルレチドを用いた治療を開始してから2カ月後に、最終コースの治療〔ビタ ミン剤と2%サリチル酸軟膏、石英及び松浴(pine bathing)の併用〕を行った 。 来院の際に、患者の顔、脚、腕、胸及び背中に数個のバッジ状病変部が認めら れた。 顔には、小さなバッジ状病変部が主として頭髪の生え際に沿って並んでいた。 脚には、脛骨の後部及び側部に小さなバッジ状病変部が散らばっており、膝にも いくつかのバッジ状病変部があった。 腕には、直径の小さい5〜6個のバッジ状病変部が両肩部にあった。 胸には1.5cmまでの直径の6個のバッジ状病変部があり、背中には10個 の小さいバッジ状病変部が主として側上部領域にあった。患者は、周期的な痒み の発作、被刺 激性及び不眠を訴えた。セルレチドジエチルアミン塩を用いた治療 4.0μgのセルレチドジエチルアミン塩を一回注射した後で、患者に著しい 睡眠の改善が認められ、痒みはそれほどひどくなくなり、患者の精神状態が改善 された。 薬剤投与後2〜3日の間に、疾患がわずかに悪化し、バッジ状病変部の数がい くらか増加した。しかし、2週間後には、全てのバッジ状病変部が軟らかく白っ ぽくなり、鱗屑は消えた。次いで、バッジ状病変部はより白っぽくより薄くなり 、治療を始めてから約1カ月半後には完全に消えた。 セルレチドジエチルアミン塩による治療後には、その後14カ月にわたって疾 患の再発は全く認められなかった。DETAILED DESCRIPTION OF THE INVENTION USE OF Serure tide diethylamine salts in the treatment of psoriasis, the use of Serure tides diethylamine salt thereof for treating psoriasis (Takus). Although the treatment of this skin disease has hitherto been carried out with etretinate (Tigason), etretinate only slightly affects the damage that can cause keratinization of the skin due to psoriasis. Furthermore, the substances may cause tolerance and teratogenic effects, especially during prolonged treatment. Celretide, a well-known decapeptide, first extracted from the skin of Hy1a caerulea (Australia frog) and then synthetically produced has the formula: And its diethylamine salt is commercially available under the trade name "Takus". In terms of therapy, ceruletide diethylamine salt is used as a stimulant for gastric secretion, and also as a diagnostic agent when examining the functional status of the gallbladder and spleen. Surprisingly, it has been found that ceruletide diethylamine salt is used in the treatment of psoriasis with very good results. Twelve volunteers (9 men, 3 women) found that ceruletide diethylamine salt was effective in treating various forms of psoriasis such as guttate psoriasis, pattern psoriasis, round psoriasis, and seborrheic psoriasis. People). The substance has been used alone to avoid synergistic pharmacological effects with drugs of other species, whereby it was possible to assess the positive action of the substance itself on skin disorders. . Administration of ceruletide diethylamine salt by a single intramuscular injection in the dose range of 2.5-5.0 μg, without exception, significantly improved the disease in all patients, such improvement being between 1 and 3 months. Continue. On the first day after administration, improvement in sleep, stabilization of mental status and reduction of itch were observed. It was observed that the scales disappeared within 1-2 weeks, the number of badger-like lesions decreased significantly, became soft and whitish, and finally disappeared. A single injection of ceruletide diethylamine salt is usually sufficient to treat guttate psoriasis. The formulation is further injected at a dose of 2.5-5.0 μg, paying attention to the individual susceptibility of the patient to ceruletide diethylamine salt, especially in the presence of non-healing badger lesions. The lesion skin regained its normal color while being treated with ceruletide diethylamine salt, but the use of conventional type ointments (eg, mercury ointment) in place of ceruletide diethylamine salt always provided depigmentation. Loss was recognized. In the case of psoriasis with alcoholism, a single dose of ceruletide diethylamine salt completely normalized the skin lesions and this positive effect lasted for about 5-6 months. Further, after the alcoholism recurred, the recurrence of psoriasis was observed within the first 1-2 months after the alcohol was restarted. Examples Example 1: Patient A. V. (Male, 20 years old, single, cook) Diagnosis: Psoriasis rotata, alcoholism. Medical history: The first signs of psoriasis were seen after a car accident that the patient experienced at the age of 15. Two to three months after the car accident, the patient's elbow was found to have blemishes and the patient's arm, leg, chest and shoulders with badged lesions. Especially in winter, the condition recurred. It was noted that a patient who had inherited a complex heredity from his father had chronic alcoholism at the age of 17 years, during which his condition worsened. After repeated treatment with tar ointment, cortisone liniment, vitamins and sedatives, no improvement was obtained. The badged lesions even disappeared, but reappeared in other places, such as the elbows and knees. On examination, the patient complained of the presence of itching and badged lesions around the elbows, arms, legs, shoulders, forehead and ears. The size of the badge lesion on the forehead of the patient was 2.5 × 3 and 5.0 × 4.0 cm 2 , and the size of the badge lesion on the inner surface of the left elbow was 6.0 × 5. 0.0 cm 2 , 3.0 x 2.5 cm 2 and 3.0 x 2.0 cm 2 , and the patient's right elbow was 8.0 x 2. There were 28 smaller badge-like lesions, as well as badge-like lesions in the form of guttate psoriasis (23 badge-like lesions) with a size of 5 cm 2 , 3 × 2.5 cm 2 . The patient's entire back had guttate psoriasis badge-like lesions and other badge-like lesions as large as coins. There were 25 badge-like lesions of guttate psoriasis and round psoriasis on the left thigh side of the patient. Most were covered with scales and 32 purple badge-like lesions with a maximum size of 4.5 × 5.5 cm 2 were inside the left thigh. There were 28 badge-like lesions ranging in size from 0.5 × 0.5 cm 2 to 1.8 × 2.0 cm 2 on the right thigh of the patient. A badge-like lesion with a diameter of 0.5 x 6.0 cm 2 was found in the superior anterior part of the patient's left tibia, but the same area of the patient's right tibia was covered with 28 purple badge-like lesions. It was Treatment with ceruletide diethylamine salt The patient was treated with a single injection of 4.9 μg ceruletide diethylamine salt. Within the day of treatment, patient A. V. , Improved sleep and decreased itching. After 2 weeks, the badge-like lesion became soft and whitish. The badge-like lesion on the back turned into a ring. One month later, spaces were seen between the badged lesions on the patient's forehead, elbows and legs. The badge-like lesion on the back became whitish and semicircular. The number of badge-like lesions on the legs decreased. The improvement of the skin disorder continued during the observation for 3 months, during which all the badged lesions disappeared. A positive effect was noted even after 10 months. The patient then occasionally began to drink alcohol again, stopped drinking after psoriasis had recurred, and had regular treatment with vitamins, quartz lamps and liniments for 41 days in a specialist clinic. Three days after finishing the treatment at the clinic, the patient started to drink alcohol again, and in the following week all symptoms of the disease were reproduced. Comparing the two treatments performed, the beneficial effect of treatment with ceruletide diethylamine salt lasted longer. Example 2: Patient N. I. (Female, 35 years old, chronic gastritis) Diagnosis: Patterned psoriasis and guttate psoriasis, chronic gastritis. Medical history: The first symptoms of psoriasis appeared 2 months after the accident. The patient was insomnia, amenorrhea and irritability. Several months after the accident, several spots appeared on the bruised area and several spots on the patient's chest and back. The patient was treated with vitamins, sedatives and tar ointments. The back and chest spots disappeared, but new spots appeared on the face, arms and legs. Depigmentation was seen on the skin where the stain had been treated. Patients complain of itching after bathing and badged lesions on the knees, legs, abdomen and arms. As for the size of the badge-shaped lesion, one badge-shaped lesion on the left leg of the patient was 5.5 × 6. At 0 cm 2 , the two badged lesions on the patient's right knee were 6.5 × 4.5 cm 2 and 2. The size was 0 × 3.5 cm 2 , and a badge-like lesion in the form of drops was found on the chest, back and inside of the patient's chest. Treatment with Ceruletide Diethylamine Salt The patient was treated with a single injection of 4.5 μg of ceruletide diethylamine salt. Within the same day after treatment with ceruletide injection, the patient was found to be free of irritability, itchiness and exfoliation of the badged lesion. One week later, the badger lesions on the patient's back and chest became whitish with small spaces between the badger lesions. The depigmented badge lesions returned to normal skin color and the improvement continued for about 4 months until all the badge lesions had disappeared and did not worsen. During the observation period and the observation period of 10 months, no skin disorder was observed in the patient. Example 3: Patient C. A. (Male, 33 years old, single, engineer) Diagnosis: Seborrheic psoriasis, chronic pyelonephritis. Medical history: Seven years ago, he was diagnosed with psoriasis during his military service. A badged lesion appeared near the forehead hair, then the entire scalp was covered with scales. There was usually a relapse of psoriasis every two months. Treatment with mercury ointment only improved temporarily, and the badge-like lesion still remained and became chronic. On arrival, the patient complained of intense itching and flaking, the presence of badger lesions on the scalp and "coronal" lesions on the forehead. The size of the purple coronal lesion on the forehead was 16 × 3.8 cm 2 . The entire surface of the scalp was covered with geographic psoriasis. The largest and thickest badge-like lesion was behind the ear. The patient was also in severe depression. Treatment with Ceruletide Diethylamine Salt The patient was treated with a single injection of 3.0 μg of ceruletide diethylamine salt. The patient had improved sleep and itching, and stable mental status. In one week, the badge-like lesion became thin and turned brown. After 3 weeks, the badge-like lesion behind the ear became pale and whitish. A large space was seen in the coronal lesion of the forehead, and the coronary lesion began to divide into a single part. The skin improvement lasted for 3 months. A second injection of 2.7 μg was given 4 months after the first injection. Peeling was significantly reduced and the coronary lesion became whitish. Badge-like lesions behind the ears decreased and became whitish and thin. The treatment was continued and no further deterioration of the patient's symptoms was observed after about 12 months, which was the result obtained from the final treatment. Example 4: Patient S. Sh. (22 years old, single, college student, basketball and track and field athlete) Diagnosis: Guttate psoriasis with gastritis. Medical history: First, a badge-like lesion of psoriasis appeared 14 months after the treatment of severe stress caused by a mental conflict was started. In autumn, the symptoms recurred. In addition, new badged lesions appeared when eating pastries, cakes and other similar products with high caloric value. The patient was cured on his own with hormonal ointment, salicylic acid and sulfur ointment, vitamins, quartz and sun bath. The badged lesions became whitish and disappeared leaving depigmented stains, but they appeared again a few weeks later. Two months after starting the treatment with ceruletide, the final course of treatment [combination of vitamin preparation with 2% salicylic acid ointment, quartz and pine bathing] was performed. On arrival, several badge-like lesions were found on the patient's face, legs, arms, chest and back. On the face, small badge-like lesions were lined up mainly along the hairline. The legs had small badge-like lesions scattered on the posterior and lateral sides of the tibia, and there were also some badge-like lesions on the knee. On the arm, there were 5 to 6 small badge-shaped lesions on both shoulders. There were 6 badge-like lesions with a diameter of up to 1.5 cm on the chest and 10 small badge-like lesions on the back mainly in the superior lateral region. The patient complained of periodic pruritus attacks, irritation and insomnia. Treatment with Ceruletide Diethylamine Salt After a single injection of 4.0 μg of ceruletide diethylamine salt, the patient noticed a significant improvement in sleep, the itch was less severe and the patient's mental status was improved. Within 2-3 days after drug administration, the disease worsened slightly and the number of badged lesions increased somewhat. However, after 2 weeks, all the badge-like lesions became soft and whitish, and the scales disappeared. The badged lesions then became whitish and thinner, and disappeared completely about a month and a half after starting treatment. After treatment with ceruletide diethylamine salt, no recurrence of disease was observed over the following 14 months.

───────────────────────────────────────────────────── フロントページの続き (81)指定国 EP(AT,BE,CH,DE, DK,ES,FR,GB,GR,IE,IT,LU,M C,NL,PT,SE),OA(BF,BJ,CF,CG ,CI,CM,GA,GN,ML,MR,NE,SN, TD,TG),AP(KE,MW,SD,SZ,UG), AM,AT,AU,BB,BG,BR,BY,CA,C H,CN,CZ,DE,DK,EE,ES,FI,GB ,GE,HU,JP,KE,KG,KP,KR,KZ, LK,LR,LT,LU,LV,MD,MG,MN,M W,MX,NL,NO,NZ,PL,PT,RO,RU ,SD,SE,SI,SK,TJ,TT,UA,US, UZ,VN─────────────────────────────────────────────────── ─── Continued front page    (81) Designated countries EP (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, M C, NL, PT, SE), OA (BF, BJ, CF, CG , CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), AP (KE, MW, SD, SZ, UG), AM, AT, AU, BB, BG, BR, BY, CA, C H, CN, CZ, DE, DK, EE, ES, FI, GB , GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, M W, MX, NL, NO, NZ, PL, PT, RO, RU , SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN

Claims (1)

【特許請求の範囲】 1.乾癬の治療に有用な薬剤を製造するためのデカペプチドセルレチド(Tak us)ジエチルアミン塩 の使用。 2.セルレチドジエチルアミン塩を2.5〜5.0μgの用量で患者に一回投与 することを特徴とする請求項1に記載の使用。 3.患者の個々の感受性を考慮して、セルレチドジエチルアミン塩を2.5〜5 .0μgの用量で患者に2回順次投与することを特徴とする請求項1に記載の使 用。 4.医薬上活性な成分として、デカペプチドセルレチドジエチルアミン塩 を含むことを特徴とする乾癬の治療用組成物。[Claims] 1. Decapeptide ceruletide (Takus) diethylamine salt for the manufacture of a medicament useful in the treatment of psoriasis Use of. 2. The use according to claim 1, characterized in that ceruletide diethylamine salt is administered to the patient once in a dose of 2.5 to 5.0 μg. 3. Considering the individual sensitivities of the patient, ceretide diethylamine salt is added to 2.5-5. Use according to claim 1, characterized in that the patient is administered twice sequentially in a dose of 0 μg. 4. Decapeptide ceretide diethylamine salt as a pharmaceutically active ingredient A composition for treating psoriasis, which comprises:
JP7521701A 1994-02-18 1995-02-13 Use of ceruletide diethylamine salt in the treatment of psoriasis Pending JPH08509245A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT94A000298 1994-02-18
ITMI940298A IT1274015B (en) 1994-02-18 1994-02-18 USE OF CERULETIDE (TAKUS) IN THE TREATMENT OF PSORIASIS
PCT/IB1995/000282 WO1995022346A1 (en) 1994-02-18 1995-02-13 Use of ceruletide diethyl amine salt in the treatment of psoriasis

Publications (1)

Publication Number Publication Date
JPH08509245A true JPH08509245A (en) 1996-10-01

Family

ID=11367909

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7521701A Pending JPH08509245A (en) 1994-02-18 1995-02-13 Use of ceruletide diethylamine salt in the treatment of psoriasis

Country Status (13)

Country Link
EP (1) EP0696203A1 (en)
JP (1) JPH08509245A (en)
AU (1) AU2146595A (en)
CA (1) CA2160251A1 (en)
FI (1) FI954912A0 (en)
HU (1) HU9503295D0 (en)
IL (1) IL112578A0 (en)
IT (1) IT1274015B (en)
MX (1) MX9504335A (en)
NO (1) NO954115D0 (en)
PL (1) PL311159A1 (en)
WO (1) WO1995022346A1 (en)
ZA (1) ZA951137B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3034531C2 (en) * 1980-09-12 1986-09-18 Farmitalia Carlo Erba S.p.A., Mailand/Milano Use of polypeptides as analgesics in human and veterinary medicine
JPS6041052B2 (en) * 1981-04-07 1985-09-13 塩野義製薬株式会社 psychotropic drugs

Also Published As

Publication number Publication date
ITMI940298A0 (en) 1994-02-18
AU2146595A (en) 1995-09-04
NO954115L (en) 1995-10-16
IT1274015B (en) 1997-07-14
MX9504335A (en) 1997-05-31
WO1995022346A1 (en) 1995-08-24
FI954912A (en) 1995-10-16
NO954115D0 (en) 1995-10-16
PL311159A1 (en) 1996-02-05
EP0696203A1 (en) 1996-02-14
ITMI940298A1 (en) 1995-08-19
IL112578A0 (en) 1995-05-26
CA2160251A1 (en) 1995-08-24
HU9503295D0 (en) 1996-01-29
FI954912A0 (en) 1995-10-16
ZA951137B (en) 1995-12-01

Similar Documents

Publication Publication Date Title
Yan et al. Aquagenic palmoplantar keratoderma
KR20140041437A (en) Therapeutic agent for alopecia
JP2002520281A (en) Vitamin E and its esters for use in the topical treatment of mucosal diseases
WO2008058210B1 (en) Local administration of gallium compositions to treat pain
Schutz et al. Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat
JPH04500824A (en) Skin treatment methods to reverse the effects of photoaging
CN112770765B (en) Composition for preventing and/or treating urogenital mucosa
US8147851B2 (en) Treating eczema and/or psoriasis
Plagens-Rotman et al. Skin and mucous membranes’ manifestations of dermatological diseases within the genital area in females
US20150071880A1 (en) Treatment of epithelial layer lesions
JPH08509245A (en) Use of ceruletide diethylamine salt in the treatment of psoriasis
CA2344677A1 (en) Improving memory by the administration of .delta.5-androstene-3.beta.-ol-7,17-dione and 3.beta. esters thereof
JPH11505238A (en) Composition for treating skin symptoms
JPH09506897A (en) Psoriasis treatment
JPS58162512A (en) Hair growing agent for premature baldness and circular loss of hair
RU2119350C1 (en) Agent for treatment of patients with psoriasis
JP2024506953A (en) PLAQUE Improvement effect of Tapinarov in the treatment of psoriasis, atopic dermatitis, and radiation dermatitis
KR20140037045A (en) (r)-1,2-propanediol for use as a solvent in therapeutic cooling agent compositions
US20070155786A1 (en) Methods for treating oral aphthous stomatitis and oral mucositis
Traub et al. NEW YORK ACADEMY OF MEDICINE, SECTION OF DERMATOLOGY AND SYPHILIS
AU2006200822B2 (en) Treatment of epithelial layer lesions
GOH et al. PIGMENTARY DEMARCATION LINES (FUTCHER'S LINE AND VOIGT'S LINE)
Hata et al. Society Transactions
Kocsard et al. Perioral dermatitis
COLCOTT ROYAL SOCIETY OF MEDICINE. 11